Article Text

Download PDFPDF
Pharmacological interventions
Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia?
  1. Leslie Citrome
  1. Correspondence to New York Medical College, Valhalla, New York, USA; citrome{at}

Statistics from

ABSTRACT FROM: Correll CU, Skuban A, Ouyang J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-Week Randomized, Double-Blind, Placebo-Controlled Trial. Am J Psychiatry 2015;172:870–80.

What is already known on this topic

Despite the availability of different antipsychotics for the treatment of schizophrenia, in clinical practice it is somewhat of a struggle to identify an antipsychotic medication for individual patients that they are willing to adhere to. Brexpiprazole is a new molecular entity that is a dopamine receptor partial agonist that differs from aripiprazole in terms of greater potency at serotonin 5-HT1A receptors and less intrinsic activity at dopamine D2 receptors.1 Brexpiprazole received approval in the USA for the treatment of schizophrenia in July 2015, based in part on two acute phase clinical trials,2 of which one is the subject of …

View Full Text


  • Competing interests In the past 36 months LC has engaged in collaborative research with, or received consulting or speaking fees, from: Acadia, Alexza, Alkermes, Allergan, AstraZeneca, Avanir, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Forum, Genentech, Janssen, Jazz, Lundbeck, Merck, Medivation, Mylan, Neurocrine, Novartis, Noven, Otsuka, Pfizer, Reckitt Benckiser, Reviva, Shire, Sunovion, Takeda, Teva, Valeant, Vanda.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.